Vasculitis News and Research

Latest Vasculitis News and Research

Chickenpox virus can cause strokes in patients with compromised immune systems

Patients infected with human immunodeficiency virus (HIV) can, in rare cases, experience bleeding on the brain that causes a type of stroke called intracerebral hemorrhage.

5 May 2015

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology.

17 Apr 2015

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US).

8 Nov 2014

Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Lupus and other rheumatologic diseases can initially present as neurological disorders such as headaches and seizures, and thus delay diagnosis for many months, according to Loyola University Medical Center neurologists.

19 Aug 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy,* and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).

13 Jun 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Same-day bilateral knee replacement surgery is safe for select patients with rheumatoid arthritis, researchers from Hospital for Special Surgery in New York have found.

14 Mar 2014

Scientific Statement details latest evidence for diagnosis and treatment of fibromuscular dysplasia

A vascular disease called fibromuscular dysplasia, which can cause high blood pressure, kidney failure, stroke and other symptoms -- mostly in women -- is "poorly understood by many healthcare providers," according to a Scientific Statement from the American Heart Association.

27 Feb 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Penn researchers receive PCORI awards to develop, expand health data network for patients, researchers

Two teams led by researchers in the Perelman School of Medicine at the University of Pennsylvania have been approved for funding awards by the Patient-Centered Outcomes Research Institute (PCORI).

31 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

Vasculitis damage swift, accumulating

Study findings reveal the significant burden of disease among patients with antineutrophil-cytoplasm antibody associated vasculitis, with many individuals showing irreversible damage shortly after diagnosis.

22 Nov 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Powerful new option for treating vasculitis

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

27 Aug 2013

Vasculitis News and Research

Latest Vasculitis News and Research

Chickenpox virus can cause strokes in patients with compromised immune systems

Inflammation plays causal role in neurologic changes associated with Lyme disease

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Scientific Statement details latest evidence for diagnosis and treatment of fibromuscular dysplasia

NICE approves MabThera for treating severe forms of GPA and MPA

Penn researchers receive PCORI awards to develop, expand health data network for patients, researchers

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Vasculitis damage swift, accumulating

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Apremilast drug shows promise for Behcet's ulcers

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Powerful new option for treating vasculitis

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vasculitis News and Research

Latest Vasculitis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in